TY - JOUR
T1 - Within and Beyond the MIC
T2 - Unveiling the Antifungal Potency of Green-Synthesized Silver Nanoparticles Against Clinical Isolates of Candida albicans
AU - Ramos-Hernández, Rodrigo
AU - González-Díaz, Francisco
AU - Salas-Téllez, Enrique
AU - Sordo, Monserrat
AU - Salazar, Ana María
AU - Ostrosky-Wegman, Patricia
AU - Yacamán, Miguel José
AU - Méndez-Albores, Abraham
AU - Vázquez-Durán, Alma
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/9
Y1 - 2025/9
N2 - Biogenic silver nanoparticles (AgNPs) synthesized using aqueous extracts of Pyracantha koidzumii (AgNPs-P) and Schinus molle (AgNPs-S) were evaluated for antifungal activity against two clinical isolates (HCI-I and HCI-II) and an ATCC strain of Candida albicans. Synthesis was confirmed by UV–Vis, Fourier transform infrared spectrophotometry (FTIR), dynamic light scattering (DLS), electrophoretic light scattering (ELS), nanoparticle tracking analysis (NTA), and transmission electron microscopy (TEM) revealing stable, quasi-spherical particles averaging 15.13 nm (AgNPs-P) and 10.81 nm (AgNPs-S). Both types of AgNPs exhibited a minimum inhibitory concentration (MIC) of 1.56 µg/mL across all strains. However, AgNPs-P demonstrated superior efficacy against HCI-I, with the lowest minimum fungistatic (6.25 µg/mL) and fungicidal concentrations (12.5 µg/mL). Notably, AgNPs-P eliminated fungal cells at a lower particle concentration (1.76 × 1010 NPs/mL) yielding a lower particle efficiency index (2.8 × 104 NPs/CFU), underscoring their enhanced antifungal efficacy. Mechanistically, the AgNPs compromised cell wall integrity, inhibited hyphal growth, and reduced proteolytic activity. These results highlight the need to evaluate antifungal performance beyond MIC values and suggest AgNPs-P as a promising therapeutic candidate.
AB - Biogenic silver nanoparticles (AgNPs) synthesized using aqueous extracts of Pyracantha koidzumii (AgNPs-P) and Schinus molle (AgNPs-S) were evaluated for antifungal activity against two clinical isolates (HCI-I and HCI-II) and an ATCC strain of Candida albicans. Synthesis was confirmed by UV–Vis, Fourier transform infrared spectrophotometry (FTIR), dynamic light scattering (DLS), electrophoretic light scattering (ELS), nanoparticle tracking analysis (NTA), and transmission electron microscopy (TEM) revealing stable, quasi-spherical particles averaging 15.13 nm (AgNPs-P) and 10.81 nm (AgNPs-S). Both types of AgNPs exhibited a minimum inhibitory concentration (MIC) of 1.56 µg/mL across all strains. However, AgNPs-P demonstrated superior efficacy against HCI-I, with the lowest minimum fungistatic (6.25 µg/mL) and fungicidal concentrations (12.5 µg/mL). Notably, AgNPs-P eliminated fungal cells at a lower particle concentration (1.76 × 1010 NPs/mL) yielding a lower particle efficiency index (2.8 × 104 NPs/CFU), underscoring their enhanced antifungal efficacy. Mechanistically, the AgNPs compromised cell wall integrity, inhibited hyphal growth, and reduced proteolytic activity. These results highlight the need to evaluate antifungal performance beyond MIC values and suggest AgNPs-P as a promising therapeutic candidate.
KW - Antifungal susceptibility test
KW - C. albicans
KW - Green synthesis
KW - Minimum fungicidal concentration
KW - Minimum fungistatic concentration
KW - Silver nanoparticles
UR - http://www.scopus.com/inward/record.url?scp=105007862736&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105007862736&partnerID=8YFLogxK
U2 - 10.1007/s12668-025-02030-1
DO - 10.1007/s12668-025-02030-1
M3 - Article
AN - SCOPUS:105007862736
SN - 2191-1630
VL - 15
JO - BioNanoScience
JF - BioNanoScience
IS - 3
M1 - 407
ER -